Receptorium 5-HT2A est receptorium serotonini et familiae receptoriorum proteino G copulatorum (classis Gq/11) cum serotonino ligando endogeno[1]. 5-HT est abbreviatura 5-hydroxy-tryptamini, quod est serotoninum.

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

Structura receptorii 5-HT2A
Receptorium serotonini 2A HTR2A
Chromosoma: 13p46.83 -46.9
Obsessum a drogis his:
Haloperidolum, Loxapinum, Quetiapinum.

In mammaliis receptoria 5-HT2A imprimis in neocortice, ibi in stratis variis (I, III, IV), reperiuntur[2].

Diversa hallucigena effectus suos cum mutationibus cognitionis et morum perceptionis per receptorium 5-HT2A exercent[3].

Medicamentum pimavanserinum agonista inversa et antagonista receptorii 5-HT2A est[4].

Nexus interni

  1. T L'Estrade E, Hansen HD, Erlandsson M, Ohlsson TG, Knudsen GM, Herth MM (2018). "Classics in Neuroimaging: The Serotonergic 2A Receptor System-from Discovery to Modern Molecular Imaging". ACS Chem Neurosci 
  2. López-Giménez J. F., Vilaró M. T., Palacios J. M., Mengod G. (Ian 2001). "Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3HMDL100,907 autoradiography and in situ hybridization studies"]. The Journal of comparative neurology 429 (4): 571-89 
  3. López-Giménez J. F., González-Maeso J. (2018). "Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways". Current topics in behavioral neurosciences 36: 45-73 
  4. Abbas A., Roth B. L. (Dec 2008). "Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders". Expert opinion on pharmacotherapy 9 (18): 3251-9